nonnucleoside reverse transcriptase inhibitors


Also found in: Dictionary, Thesaurus.
Related to nonnucleoside reverse transcriptase inhibitors: nucleotide reverse transcriptase inhibitors, Protease inhibitors

nonnucleoside reverse transcriptase inhibitors (NNRTI)

a class of antiretroviral drugs that inhibit human immunodeficiency virus replication by blocking the reverse transcriptase enzyme essential for viral replication. These drugs have a different mechanism of action and side-effect profile from other reverse transcriptase inhibitors. See also nucleoside reverse transcriptase inhibitors.

non·nu·cle·o·side re·verse tran·scrip·tase in·hib·i·tors

(NNRTIs) (non-nū'klē-ō-sīd rĕ-vĕrs' trans-krip'tās in-hib'i-tŏrz)
Class of medications to treat HIV infection (e.g., efavirenz, nevirapine).
References in periodicals archive ?
Evidence from the only national random sample of HIV patients (the HIV Cost and Services Utilization Study--HCSUS) also found that women were less likely to receive therapies involving protease inhibitors or nonnucleoside reverse transcriptase inhibitors (therapy involving these drugs is often referred to as highly active antiretroviral therapy or HAART) immediately after their diffusion (Shapiro et al.
For each enrollee in our sample, payments related to an inpatient admission not including related physician payments, payments related to outpatient services not including related physician payments, payments to physicians (inpatient and outpatient), payments for HIV-related drugs, payments for protease inhibitors and nonnucleoside reverse transcriptase inhibitors, and payments for all drugs were assembled and analyzed.
7 percent) with HIV disease received a protease inhibitor or nonnucleoside reverse transcriptase inhibitor compared to 31 percent of privately insured women (95 percent confidence interval: 26.
This study also found that 89 percent of men who took antiretroviral drugs received a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor while 77 percent of the women who took HIV drugs received a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor (this gender difference is statistically significant at the 99 percent level).
6 percent less likely than men with HIV disease receiving antiretroviral medications to have received a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor after taking into account all of the other explanatory variables in the model.
4 percent) received a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor.
The results of multivariate logit analyses reveal that the probability that a woman received an antiretroviral drug was less than one-third that of a man (see Table 3), and that the probability a woman received a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor conditional on receipt of an antiretroviral drug was less than one-half that of a man (see Table 4).
BOSTON--HIV-infected patients treated with an antiretroviral regimen that included a nonnucleoside reverse transcriptase inhibitor are less likely to develop primary HIV brain pathology than are those who never received one of these agents, according to an autopsy study.
For example, at-risk patients on a regimen that includes protease inhibitors should be switched to nonnucleoside reverse transcriptase inhibitors or to an ART agent that has been shown to have lesser effects on lipids, such as atazanavir (Reyataz), Dr.
The other enrolled 504 patients at medical centers in Europe and Australia, All patients had to have failed treatment with all three of the available classes of anti-MW drugs: nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors.
During treatment interruption, 18 of the 22 patients (81%) experienced a complete shift in susceptibility to protease inhibitor therapy, and 16 of the 22 patients had a complete shift in susceptibility to nonnucleoside reverse transcriptase inhibitors, Dr.